$248 Million

Passage Bio

Initial Public Offering

Bookrunner, February 2020

Passage Bio, Inc. is a genetic medicines company focused on the development of transformative therapies to treat rare, monogenic central nervous system (CNS) diseases with a high unmet medical need.

More Like This

Jul 2020
$144 Million

Initial Public Offering

Sole Bookrunner

View Details
Jun 2020
$244 Million

Initial Public Offering

Bookrunner

View Details
Jun 2020
$213 Million

Initial Public Offering

Bookrunner

View Details